Abstract
Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Inhaled Corticosteroids In Treatment of Cystic Fibrosis
Volume: 11 Issue: 3
Author(s): Ela Erdem and Refika Ersu
Affiliation:
Keywords: Inhaled corticosteroids, cystic fibrosis, adverse effects
Abstract: Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.
Export Options
About this article
Cite this article as:
Erdem Ela and Ersu Refika, Inhaled Corticosteroids In Treatment of Cystic Fibrosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (3) . https://dx.doi.org/10.2174/1871523011202030206
DOI https://dx.doi.org/10.2174/1871523011202030206 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Milk has Anti-Oxidant Properties to Protect Premature Infants
Current Pediatric Reviews Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors
Reviews on Recent Clinical Trials Induction of Strong Anti-HIV Cellular Immunity by a Combination of Clostridium Perfringens Expressing HIV Gag and Virus Like Particles
Current HIV Research Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Multifunctional Dendritic Drug Delivery Systems: Design, Synthesis, Controlled and Triggered Release
Current Topics in Medicinal Chemistry Inhibition of Cyclooxygenase Enzyme by Bioflavonoids in Horsegram Seeds Alleviates Pain and Inflammation
Combinatorial Chemistry & High Throughput Screening Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Stress-Free Chromatography: IEC and HIC
Current Pharmaceutical Biotechnology The Adiponectin Signaling Pathway as a Novel Pharmacological Target
Mini-Reviews in Medicinal Chemistry COVID-19 in G6PD-deficient Patients, Oxidative Stress, and Neuropathology
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: “Amniotic Fluid Embolism: Novel Biomarkers for Future Diagnostic Investigation and Therapy”)
Current Pharmaceutical Biotechnology Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Cytokines as Immunomodulators in Tuberculosis Therapy
Recent Patents on Anti-Infective Drug Discovery Carbonic Anhydrase Activation and the Drug Design
Current Pharmaceutical Design New Developments in Peroxidation of Polyunsaturated Fatty Acids
Letters in Organic Chemistry Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research